For: | Ojima H, Yamagishi S, Shimada K, Shibata T. Establishment of various biliary tract carcinoma cell lines and xenograft models for appropriate preclinical studies. World J Gastroenterol 2016; 22(40): 9035-9038 [PMID: 27833395 DOI: 10.3748/wjg.v22.i40.9035] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v22/i40/9035.htm |
Number | Citing Articles |
1 |
Yasunari Sakamoto, Seri Yamagishi, Takuji Okusaka, Hidenori Ojima. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines. Cells 2019; 8(9): 1026 doi: 10.3390/cells8091026
|
2 |
Yusuke Takemura, Hidenori Ojima, Go Oshima, Masahiro Shinoda, Yasushi Hasegawa, Minoru Kitago, Hiroshi Yagi, Yuta Abe, Shutaro Hori, Yoko Fujii‐Nishimura, Naoto Kubota, Yuki Masuda, Taizo Hibi, Michiie Sakamoto, Yuko Kitagawa. Gamma‐synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma. Cancer Medicine 2021; 10(16): 5599 doi: 10.1002/cam4.4121
|
3 |
Qingfan Zheng, Bin Zhang, Changfeng Li, Xuewen Zhang. Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.850732
|
4 |
Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi. Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience. Journal of Clinical Medicine 2024; 13(9): 2718 doi: 10.3390/jcm13092718
|
5 |
Silvestre Vicent, Ruby Lieshout, Anna Saborowski, Monique M. A. Verstegen, Chiara Raggi, Stefania Recalcati, Pietro Invernizzi, Luc J. W. van der Laan, Domenico Alvaro, Diego F. Calvisi, Vincenzo Cardinale. Experimental models to unravel the molecular pathogenesis, cell of origin and stem cell properties of cholangiocarcinoma. Liver International 2019; 39(S1): 79 doi: 10.1111/liv.14094
|
6 |
Yasunari Sakamoto, Seri Yamagishi, Yoshinori Tanizawa, Masaomi Tajimi, Takuji Okusaka, Hidenori Ojima. PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. Japanese Journal of Clinical Oncology 2018; 48(4): 396 doi: 10.1093/jjco/hyy011
|
7 |
Jihoon Kang, Ji-Young Lee, Sunmin Lee, Danbee Kim, Jinyeong Lim, Ha Ra Jun, Seyeon Jeon, Young-Ae Kim, Hye Seon Park, Kyu-pyo Kim, Sung-Min Chun, Hee Jin Lee, Changhoon Yoo. Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer. Cancer Research and Treatment 2023; 55(1): 219 doi: 10.4143/crt.2021.1166
|
8 |
Jennifer L. Leiting, Stephen J. Murphy, John R. Bergquist, Matthew C. Hernandez, Tommy Ivanics, Amro M. Abdelrahman, Lin Yang, Isaac Lynch, James B. Smadbeck, Sean P. Cleary, David M. Nagorney, Michael S. Torbenson, Rondell P. Graham, Lewis R. Roberts, Gregory J. Gores, Rory L. Smoot, Mark J. Truty. Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. JHEP Reports 2020; 2(2): 100068 doi: 10.1016/j.jhepr.2020.100068
|